

Supplementary Table 1. Clinical characteristics of patients treated for recurrent HCV according to recipient : donor IL28B genotype

	Donor non-CC / Recip non-CC	Donor CC / Recip non-CC	Donor non-CC / Recip CC	Donor CC / Recip CC	P-value
N*	19	22	12	7	
Age, yrs (median, IQR)	51 (48 - 57)	52 (46 - 58)	50 (47 - 57)	53 (51 - 59)	0.6353
Donor age, yrs (median, IQR)	54 (31 - 61)	34 (22 - 51)	46 (24 - 58)	42 (35 - 49)	0.1437
Gender	16 (84%)	14 (64%)	9 (75%)	5 (71%)	0.5246
Ethnicity					
Caucasian	15 (79%)	20 (90%)	12 (100%)	7 (100%)	0.8433
African American	1 (5%)	0 (0%)	0 (0%)	0 (0%)	
Other	3 (16%)	2 (10%)	0 (0%)	0 (0%)	
HCV RNA level, log₁₀ IU/mL (median, IQR)	6.3 (5.5 – 6.7)	6.5 (6.1 – 6.8)	5.5 (5.2 – 6.1)	6.0 (5.5 – 6.1)	0.0155
HCV genotype**					
1	13 (76%)	16 (73%)	7 (64%)	4 (67%)	0.7035
2	3 (18%)	3 (14%)	1 (9%)	1 (17%)	
3	0 (0%)	2 (9%)	3 (27%)	2 (17%)	
4	1 (6%)	1 (5%)	0 (0%)	0 (0%)	
Fibrosis stage					
0	13 (68%)	10 (45%)	6 (50%)	4 (57%)	0.1351
1	2 (11%)	5 (23%)	3 (25%)	0 (0%)	
2	1 (5%)	3 (14%)	3 (25%)	0 (0%)	
3	3 (16%)	4 (18%)	0 (0%)	2 (29%)	
4	0 (0%)	0 (0%)	0 (0%)	1 (14%)	
Warm ischemia time (median, IQR)	47 (36-51)	49 (38 - 60)	56 (37 - 60)	44 (42 - 67)	0.8561
Cold ischemia ime (median, IQR)	479 (362-514)	444 (411 - 504)	424 (378 - 456)	453 (356 - 508)	0.96

Interval between LT and HCV recurrence (median, IQR)	0.61 (0.29-2.49)	1.0 (0.38 - 2.33)	0.60 (0.28 - 2.89)	0.95 (0.29 - 2.02)	0.9357
pegIFN vs standard IFN	16 (84%)	15 (68%)	10 (83%)	4 (57%)	0.3855
RBV combination therapy***	14 (78%)	20 (95%)	12 (100%)	7 (100%)	0.4435
EPO therapy	8 (42%)	10 (45%)	7 (58%)	2 (33%)	0.7433
Dose reduction	10 (53%)	19 (86%)	10 (83%)	6 (86%)	0.06
Treatment duration	47 (23 – 73)	50 (32 – 60)	34 (20 – 52)	54 (32 – 76)	0.3087
SVR	3/19 (16%)	11/22 (50%)	5/12 (42%)	6/7 (86%)	0.0095

Data = n (%) unless otherwise indicated

* 5 patients could not be evaluated for SVR

** HCV genotype missing in 4

*** Missing in 2